Bristol-Myers Squibb(BMY) ZACKS·2025-01-27 23:50Company Performance - Bristol Myers Squibb (BMY) closed at 1.46 per share, indicating a year-over-year decline of 14.12% [2] - Revenue is expected to reach $11.56 billion, representing a 0.76% increase compared to the same quarter last year [2] Analyst Estimates - Recent changes to analyst estimates for Bristol Myers Squibb are being closely monitored, as they often indicate shifts in near-term business trends [3] - Positive estimate revisions are interpreted as favorable signs for the company's business outlook [3] Zacks Rank and Valuation - The Zacks Rank system, which evaluates estimate changes, currently ranks Bristol Myers Squibb at 3 (Hold), with the Zacks Consensus EPS estimate having decreased by 1.61% in the past month [5] - The company has a Forward P/E ratio of 8.44, which is significantly lower than the industry average of 22.83, and a PEG ratio of 2.11 compared to the industry average of 1.36 [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Bristol Myers Squibb, has a Zacks Industry Rank of 70, placing it in the top 28% of over 250 industries [7] - Historically, the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]